![Jasper Clube](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jasper Clube
Gründer bei SNIPR Biome ApS
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Allan Bradley | M | 64 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 14 Jahre |
Edward Blackall Fuchs | M | 55 |
Folium Food Science Ltd.
![]() Folium Food Science Ltd. Miscellaneous Commercial ServicesCommercial Services Folium Food Science Ltd. engages in research and development on biotechnology. The company was founded by Jasper Clube, Edward Blackall Fuchs, and Christian Groendahl on November 16, 2016 and is headquartered in Cambridge, the United Kingdom. | 8 Jahre |
Christian Gröndahl | M | 60 |
SNIPR Biome ApS
![]() SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | 7 Jahre |
Morten Otto Sommer | M | 43 |
SNIPR Biome ApS
![]() SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | 7 Jahre |
Christian Groendahl | M | 60 |
Folium Food Science Ltd.
![]() Folium Food Science Ltd. Miscellaneous Commercial ServicesCommercial Services Folium Food Science Ltd. engages in research and development on biotechnology. The company was founded by Jasper Clube, Edward Blackall Fuchs, and Christian Groendahl on November 16, 2016 and is headquartered in Cambridge, the United Kingdom. | 8 Jahre |
Timothy James Rink | M | 78 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Simone Song | F | 59 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Paul Kellam | M | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Douglas Fearon | M | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Volker Germaschewski | M | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Erwin Boos | M | 46 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Tan Li | F | 60 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Timothy Nigel Carl Wells | M | 62 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Christian Itin | M | 59 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Nigel Clark | M | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Glenn Alfons Friedrich | M | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Regina Hodits | M | 53 |
SNIPR Biome ApS
![]() SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | - |
Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 Jahre |
Paul Little | M | 77 |
Folium Food Science Ltd.
![]() Folium Food Science Ltd. Miscellaneous Commercial ServicesCommercial Services Folium Food Science Ltd. engages in research and development on biotechnology. The company was founded by Jasper Clube, Edward Blackall Fuchs, and Christian Groendahl on November 16, 2016 and is headquartered in Cambridge, the United Kingdom. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ian Tomlinson | M | - |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 6 Jahre |
Robert Welna | M | - |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 5 Jahre |
Gregory Perry | M | 63 |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | - |
Robert Connelly | M | 63 |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 6 Jahre |
John Chiplin | M | 66 |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | - |
Paul Eckburg | M | 54 |
SNIPR Biome ApS
![]() SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | - |
Simon Warner | M | - |
Folium Food Science Ltd.
![]() Folium Food Science Ltd. Miscellaneous Commercial ServicesCommercial Services Folium Food Science Ltd. engages in research and development on biotechnology. The company was founded by Jasper Clube, Edward Blackall Fuchs, and Christian Groendahl on November 16, 2016 and is headquartered in Cambridge, the United Kingdom. | 2 Jahre |
Neil Brewis | M | 57 |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 5 Jahre |
Ben Woolven | M | - |
Domantis Ltd.
![]() Domantis Ltd. Pharmaceuticals: MajorHealth Technology Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom. | 7 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigtes Königreich | 24 | 85,71% |
Dänemark | 4 | 14,29% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jasper Clube
- Persönliches Netzwerk